All In Biotech

Drug Trial Radar · NCT06727604

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Dec 17, 2024

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Immunovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Dec 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.

Conditions

  • Graves' Disease

Interventions

  • IMVT-1402Drug

    600 mg SC QW for 52 weeks

  • IMVT-1402Drug

    600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks

  • PlaceboDrug

    SC QW for 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who are euthyroid (local laboratory T3 [Total T3 or FT3], FT4, and TSH values within normal limits) and off ATD at Week 26Time frame: Week 26

Locations

134 sites in 10 countries. Site status is shown where the registry gives one.

  • Site Number - 1032

    Phoenix, Arizona · Withdrawn

  • Site Number - 1036

    Phoenix, Arizona · Recruiting

  • Site Number - 1061

    Huntington Beach, California · Recruiting

  • Site Number - 1001

    Los Angeles, California · Recruiting

  • Site Number - 1047

    Los Angeles, California · Recruiting

  • Site Number - 1062

    Orange, California · Recruiting

  • Site Number - 1046

    Sacramento, California · Recruiting

  • Site Number - 1034

    San Francisco, California · Recruiting

  • Site Number - 1035

    Santa Clarita, California · Withdrawn

  • Site Number - 1005

    Torrance, California · Recruiting

  • Site Number - 1006

    Walnut Creek, California · Withdrawn

  • Site Number - 1013

    Englewood, Colorado · Recruiting

  • Site Number - 1010

    Newark, Delaware · Recruiting

  • Site Number - 1040

    Washington D.C., District of Columbia · Recruiting

  • Site Number - 1029

    Clearwater, Florida · Recruiting

  • Site Number - 1055

    Jacksonville, Florida · Recruiting

  • Site Number - 1056

    Jacksonville, Florida · Recruiting

  • Site Number - 1028

    Miami, Florida · Recruiting

  • Site Number - 1065

    Miami, Florida · Recruiting

  • Site Number - 1064

    Ocoee, Florida · Recruiting

  • Site Number - 1011

    Orlando, Florida · Withdrawn

  • Site Number - 1016

    Port Charlotte, Florida · Recruiting

  • Site Number - 1012

    West Palm Beach, Florida · Withdrawn

  • Site Number - 1038

    Atlanta, Georgia · Recruiting

  • Site Number - 1053

    Macon, Georgia · Recruiting

  • Site Number - 1020

    Stockbridge, Georgia · Withdrawn

  • Site Number - 1027

    Indianapolis, Indiana · Recruiting

  • Site Number - 1041

    Kansas City, Kansas · Recruiting

  • Site Number - 1045

    Bowling Green, Kentucky · Recruiting

  • Site Number - 1054

    Florence, Kentucky · Recruiting

  • Site Number - 1063

    Metairie, Louisiana · Recruiting

  • Site Number - 1022

    New Orleans, Louisiana · Recruiting

  • Site Number - 1048

    Shreveport, Louisiana · Recruiting

  • Site Number - 1023

    Baltimore, Maryland · Recruiting

  • Site Number - 1026

    Boston, Massachusetts · Recruiting

  • Site Number - 1018

    Farmington Hills, Michigan · Recruiting

  • Site Number - 1069

    Flint, Michigan · Recruiting

  • Site Number - 1008

    Rochester, Minnesota · Recruiting

  • Site Number - 1068

    Gulfport, Mississippi · Recruiting

  • Site Number - 1017

    Omaha, Nebraska · Recruiting

Showing 40 of 134 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.